Platelet activating factor and thromboxane B2 production after cardiopulmonary bypass

Journal of Investigative Surgery

Volumn 10, Issue 3, 1997, Pages 87-95

  Ansley, David M ^a,b   Qayumi, A Karim ^a   Duncan, Sharon ^a   Merrick, Pamela M ^a   Klein, Rael ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

Cardiac revascularization surgery; Extracorporeal circulation; Ischemia reperfusion injury; Mediators of inflammation

Indexed keywords

ADRENALIN; DOPAMINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2;

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LEFT CORONARY ARTERY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REPERFUSION INJURY; UNSTABLE ANGINA PECTORIS;

EID: 12644249107     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.3109/08941939709032138     Document Type: Article

References (30)

1. Mangano DT. Biventricular function after myocardial revascularization in humans: deterioration and recovery patterns during the first 24 hours. Anesthesiology. 1985;62: 571-577.
2. Breisblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol. 1990;15:1261-1269.
3. Leung JM, O'Kelly BF, Mangano DT. Relationship of regional wall motion abnormalities to hemodynamic indices of myocardial oxygen supply and demand in patients undergoing CABG surgery. Anesthesiology. 1990;73:802-814.
4. Weintraub WS, Jones EL, Craver J, et al. Determinants of prolonged length of hospital stay after coronary bypass surgery. Circulation. 1989;80:276-284.
5. Turnbull KW, Miyagashima RT, Gerein AN. Pulmonary complications and cardiopulmonary bypass: a clinical study in adults. Canad Anaesth Soc J. 1974;21:181-194.
6. Forman MB, Virmani R, Puett DW. Mechanisms and therapy of myocardial reperfusion injury. Circulation. 1990;81(IV):69-78.
7. McCord JM. Oxygen-derived radicals: a link between reperfusion injury and inflammation. Federation Proc 1987;46:2402-2406.
8. Benveniste J, Chignard M. A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases? Circulation. 1985;72:713-717.
9. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 1990;259:C697-C708.
10. LeGall JR, Brun-Buisson C, Trunet P, et al. Influence of age, previous health status, and severity of illness on outcome from intensive care. Crit Care Med. 1982;10:575-577.
11. Montrucchio G, Alloatti G, Tetta C, et al. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol. 1989;256:H1236-H1246.
12. Maruyama M, Farber NE, Vercellotti GM, Jacob HS, Gross GJ. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. Am Heart J. 1990;120: 510-520.
13. McManus LM, Pinckard RN. Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit. Am J Pathol. 1985;121:55-68.
14. Heffner JE, Shoemaker SA, Canham M, et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. J Clin Invest. 1983;71:351-357.
15. Shaw JO, Picknard RN, Ferrigni KS, McManus LM, Hanahan DJ. Activation of human neutrophils with 1-0-hexadecyl/octadecyl-2-acetylsn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol 1981;127:1250-1255.
16. Qayumi AK, Jamieson WRE, Poostizadeh A. Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation. Ann Thorac Surg. 1991;52:1026-1032.
17. Taniguchi H, Iwasaka T, Takayama Y, Sugiura T, Inada M. Role of platelet-activating factor in pulmonary edema after coronary ligation in dogs. Chest. 1992;102:1245-1250.
18. Chopra K, Singh M, Gupta S, Ganguly NK. Involvement of oxygen free radicals in the action of BN 52021 (PAF antagonist) to limit myocardial infarct size. Methods Find Exp Clin Pharmacol. 1993;15(7):437-445.
19. Hofer RE, Christopherson TJ, Scheithauer BW, Milde JH, Lanier WL. The effect of a platelet activating factor antagonist (BN52021) on neurologic outcome and histopathology in a canine model of complete cerebral ischemia. Anesthesiology. 1993;79:347-353.
20. May GR, Paul W, Crook P, Butler KD, Page CP. The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit. Br J Pharmacol. 1992;106:133-138.
21. Zehr KJ, Poston RS, Lee PC, et al. Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg. 1995;59:328-335.
22. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993;55: 552-559.
23. Hoshikawa-Fujimura AY, Auler Junior JO, DaRocha TR, et al. PAF-acether, superoxide anion and beta-glucuronidase as parameters of polymorphonudear cell activation associated with cardiac surgery and cardiopulmonary bypass. Braz J Med Biol Res. 1989;22(9):1077-1082.
24. Nathan N, Denizot Y, Feiss P, Ladkar M, Arnoux B, Benveniste J. Variations of blood PAF-acether levels during coronary artery surgery. J Cardiothorac Vasc Anesth. 1992;6:692-696.
25. Kim YD, Danchak RM, Heim KF, Lees DE, Myers AK. Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Prostaglandins 1993;46(3): 269-276.
26. Chen C-R, Voekel NF, Chang S-W. Platelet-activating factro potentiates protamine-induced lung edema. Am J Respir Crit Care Med. 1994;149:34-40.
27. Argiolas L, Fabi F, del Basso P. Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclooxygenase metabolites. Br J Pharmacol. 1995;114(1):203-209.
28. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg, 1994;108:626-635.
29. Frering B, Philip I, Dehoux M, et al. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;108:636-641.
30. Squadrito F, Ioculano M, Altavilla D, et al. Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury. J Lipid Med. 1993;8(1):53-65.